{"id":71660,"date":"2022-03-02T12:26:06","date_gmt":"2022-03-02T11:26:06","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/"},"modified":"2022-03-09T10:52:46","modified_gmt":"2022-03-09T09:52:46","slug":"accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/","title":{"rendered":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis"},"content":{"rendered":"

Accure Therapeutics<\/a>, a private translational neuroscience R&D company based in the Barcelona Science Park, and Oculis<\/a>, a global ophthalmology company developing life changing treatments to save sight and improve eye care with breakthrough innovations, today announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01 a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina.<\/strong><\/p>\n

ACT-01, which is being renamed OCS-05, is a first in class small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation and neurodegeneration. Its mechanism of action is related to the activation of the trophic factor pathways such as IGF 1 and B DNF. In ophthalmology, this action can protect the nerve axons in conditions where the optic nerve is affected such as in acute optic neuritis and glaucoma, where the OCS-05 could prevent chronic vision loss.<\/p>\n

Based on positive preclinical data and results of a phase I safety and PK study in healthy volunteers, a phase 2a study was initiated (the ACUITY study). ACUITY is a two-arm, randomized, double-blind, placebo-controlled, monocentric study to evaluate the safety and tolerability of OCS-05 compared to placebo in patients with acute optic neuritis. In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures. The study is ongoing at the La Piti\u00e9-Salp\u00eatri\u00e8re hospital in Paris, within the neurology-ophthalmology network of the Public University Hospital Group in Paris (APHP). One third of the planned sample size has been enrolled.<\/p>\n

Oculis is currently planning the expansion of the program in ophthalmology working with the regulatory agencies in the US, EU and China amongst others.<\/p>\n

Riad Sherif<\/strong>, M.D., CEO of Oculis, said: “We are excited about this agreement as it combines Oculis\u2019 ophthalmology expertise with Accure\u2019s unique neuroprotective approach to help transform the treatment of neurodegenerative diseases in ophthalmology. At Oculis, our focus is on building a highly innovative and differentiated pipeline providing life changing treatments for ocular unmet medical needs, and OCS-05 is a perfect fit for that ambition. Glaucoma is a leading global cause of irreversible blindness, and despite IOP lowering treatments, a significant proportion of patients still go blind. With OCS-05, we have the potential to bring to market the first neuroprotective for glaucoma and other optic neuropathies.”<\/p>\n

Laurent Nguyen<\/strong>, M.D., co-founder and CEO at Accure Therapeutics, said: “Having shown promising early data and potential in a number of ocular disease indications, the timing is right for a partnership between two like-minded companies committed to patients and driven by a passion for neuroscience. By leveraging its expertise in ophthalmology, Oculis has the potential to fulfill the promise of this exciting asset in a wide range of neurodegenerative diseases.”<\/p>\n

In reference experimental animal models of acute optic neuritis (acute inflammatory demyelinating disorder of the optic nerve) and high pressure glaucoma (high eye pressure damaging the optic nerve and leading to permanent vision loss), OCS-05 reduces damage to the optic nerve and retina. It also decreases paralysis progression in an autoimmune encephalomyelitis animal model for multiple sclerosis (inflammation caused by the body\u2019s immune system, which destroys nerve cell processes and myelin in the brain and spinal cord). Data from a completed phase I study show the safety and tolerability of single and multiple doses of OCS-05 in healthy volunteers.<\/p>\n

Under the terms of the agreement, Accure Therapeutics will receive an upfront payment, potential milestone payments upon the achievement of certain development and commercial milestones, and tiered royalties on sales.<\/p>\n

Anthony Rosenberg<\/strong>, chairman of Oculis\u2019 Board of Directors, said: “The addition of OCS-05 to Oculis\u2019 pipeline is very much in line with the Company\u2019s strategy to develop transformative therapies that address the root cause of ocular disease to improve patients sight and quality of life. There is a clear need for first in class therapies that can protect and prevent damage to the optic nerve and retina. Oculis has the team and expertise to bring OCS-05 through clinical trials and ultimately t o patients around the world.”<\/p>\n

Montserrat Vendrell<\/strong>, chairman of Accure Therapeutics and partner at Alta Life Sciences added: This licensing deal with Oculis is a proof of concept of the value creation that Accure Therapeutics brings as a translational R&D engine, taking forward truly unique science that spun off from the University of Barcelona. This licensing agreement will enhance Accure\u2019s capabilities to accelerate and expand value potential for the rest of its pipeline.<\/p>\n

Accure Therapeutics was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I, and supported by CDTI (Centre for Technological and Industrial Development). Iproteos, a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona (UB), and Bionure, a spin-off from IDIBAPS (August Pi i Sunyer Biomedical Research Institute) and CSIC (Spanish National Research Council) became part of the Accure.<\/p>\n

\u00bb For further information: Accure Therapeutics website [+]<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Accure Therapeutics, a private translational neuroscience R&D company based in the Barcelona Science Park, and Oculis, a global ophthalmology company developing life changing treatments to save sight and improve eye…<\/p>\n","protected":false},"author":14,"featured_media":71654,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-71660","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"acf":[],"yoast_head":"\nAccure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Accure Therapeutics, a private translational neuroscience R&D company based in the Barcelona Science Park, and Oculis, a global ophthalmology company developing life changing treatments to save sight and improve eye...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-02T11:26:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-09T09:52:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"674\" \/>\n\t<meta property=\"og:image:height\" content=\"655\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis\",\"datePublished\":\"2022-03-02T11:26:06+00:00\",\"dateModified\":\"2022-03-09T09:52:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/\"},\"wordCount\":834,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Laurent-Nguyen.jpg\",\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/\",\"name\":\"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Laurent-Nguyen.jpg\",\"datePublished\":\"2022-03-02T11:26:06+00:00\",\"dateModified\":\"2022-03-09T09:52:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Laurent-Nguyen.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/Laurent-Nguyen.jpg\",\"width\":674,\"height\":655},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/","og_locale":"en_US","og_type":"article","og_title":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona","og_description":"Accure Therapeutics, a private translational neuroscience R&D company based in the Barcelona Science Park, and Oculis, a global ophthalmology company developing life changing treatments to save sight and improve eye...","og_url":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2022-03-02T11:26:06+00:00","article_modified_time":"2022-03-09T09:52:46+00:00","og_image":[{"width":674,"height":655,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis","datePublished":"2022-03-02T11:26:06+00:00","dateModified":"2022-03-09T09:52:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/"},"wordCount":834,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg","articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/","url":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/","name":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg","datePublished":"2022-03-02T11:26:06+00:00","dateModified":"2022-03-09T09:52:46+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2022\/03\/Laurent-Nguyen.jpg","width":674,"height":655},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Accure Therapeutics Licenses Neuroprotective Drug Candidate to Ophthalmology Company Oculis"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=71660"}],"version-history":[{"count":6,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71660\/revisions"}],"predecessor-version":[{"id":71729,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/71660\/revisions\/71729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/71654"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=71660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=71660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=71660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}